OVERVIEW

Pharma Japan 2021 is organized by Reuters Events Pharma and will be held from Sep 14 - 16, 2021.

Overview:
We are at a turning point; the disruption caused by COVID-19 has proven that pharma can adopt digital technologies, transform long-standing business practices, and accelerate timelines to deliver value for HCPs and patients. We’ve set a new set of expectations for stakeholders across healthcare, reimagined the rules of engagement, and opened up new lines of collaboration across the lifecycle for so long previously out of grasp.

Now, instead of falling into a new status quo we must pledge to continue this momentum, embrace the power of community, and create a more sustainable healthcare system built around patient need. Returning for its 15 year, Reuters Events Japan is where our industry’s leaders come to further fuel change.

It’s the only event that brings together teams from across the lifecycle. So, whether you’re a leader in commercial strategy, marketing, medical affairs, clinical or patient engagement, this is the place you will find your vision of the future.

Our essential themes for 2021:
• A new era of collaboration, a new era of medical innovation:
Ensure a more sustainable future by partnering with stakeholders across healthcare to better represent diverse patient populations, communicate the value of new medicines, and navigate regulatory pathways
• Achieve unprecedented customer engagement:
Integrate agile operating models to enable close-loop marketing, linking insights from all channels to better inform digital investment, personalize content for HCPs and patients, and define new hybrid-field team strategies
• Empower Medical Affairs to deliver new stakeholder value:
Meet evolving HCP and patient needs by honing the role of the MSL in external engagement, upskilling and capability building for new digital norms, and redefining performance measures they reflect the transforming healthcare environment
• Scale digital-trials to ensure patient-preferred trials:
Meet patient unmet needs and accelerate regulatory approval by creating an integrated evidence approach across your trials - use real-world evidence (RWE) in combination with AI advancements to discover new insights and support trial design, execution, and outcomes
• Japan's contribution to the global pharmaceutical industry and innovations in life sciences:
Foster a science ecosystem and improve Japan's ability of active collaboration across regions by building a healthcare platform to catalyse research and science innovation

Additional details will be posted as soon as information is available.